Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial
ROCKVILLE, Md., Oct. 4, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase I trial to test Neuralstem's human spinal cord stem cells, NSI-566, in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will update trial data at the American Neurological Association annual meeting on Monday, October 8th (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3311). Dr. Feldman's poster presentation, "Completion and Outcomes of Phase I Intraspinal Stem Cell Transplantation Trial for ALS," will be up from 11:30-6:30. Dr. Feldman will be discussing the data between 5:30-6:30. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
Dr. Feldman is the President of the American Neurological Association, as well as Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. Dr. Feldman is an unpaid consultant to Neuralstem.
Never trust anyone's - "buy": you feel like holding their bag? - "hold": as they're cashing out, you're left bleeding. - "sell": oops, someone's missed the train.
The best place for big board plays: GoodFellas $tock Mafia Plays
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.